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Nurse led care
Comment in This week in the BMJ is
misleading
Editor—Readers of the paragraph in This
week in the BMJ for the paper by Walsh et al
are offered the conclusion that investment in
intermediate care in community hospitals
may be more cost effective than financing
nurse led care for post-acute patients in acute
hospitals.1 2 But the study itself, which
confirms existing evidence on the costs of
nurse led intermediate care in acute set-
tings,3 4 tackles neither the effect nor the cost
of intermediate care in community hospitals.
How then can such a conclusion be
drawn? Walsh et al do not make this
assertion. The author of the comment offers
no support. Our own review of the evidence
on nurse led intermediate care found no
quality evidence for either the effect or cost
of intermediate care in community settings.5
The BMJ has been at the
forefront of setting standards
for the reporting of primary
research. However, the edi-
tors must be aware that many
readers simply pick up a take
home message from com-
ment, like this,1 in the jour-
nal. Reviewers of research
papers are asked to ensure
that the evidence presented
supports the conclusions
made. Sadly, the same stand-
ard does not seem to be
applied to editorial comment
in the journal. Editorial opin-
ion is one thing but such
comment, which implies the support of evi-
dence from the paper, is surely not
appropriate.
Peter Griffiths senior lecturer
King’s College London, London SE1 8WA
peter.griffiths@kcl.ac.uk
Competing interests: PH is the author of much
related research and has been identified in the
past as an advocate of the nurse led unit model
of care.
1 Nurse led intermediate care may not be cost effective in
acute hospitals [This Week in the BMJ]. BMJ 2005;330:0-a.
(26 March.)
2 Walsh B, Steiner A, Pickering RM, Ward-Basu J. Economic
evaluation of nurse led intermediate care versus standard
care for post-acute medical patients: cost minimisation
analysis of data from a randomised controlled trial. BMJ
2005;330:699. (26 March.)
3 Richardson G, Griffiths P, Spilsbury P, Wilson-Barnett J,
Batehup L. Economic evaluation of a nursing-led interme-
diate care unit. Int J Technol Assess Health Care 2001;17:
442-50.
4 Griffiths P, Harris R, Richardson G, Hallett N, Heard S,
Wilson-Barnett J. Substitution of a nursing-led inpatient
unit for acute services: randomised controlled trial of out-
comes and cost of nursing-led intermediate care. Age Age-
ing 2001;2001:483-8.
5 Griffiths P, Edwards M, Forbes A, Harris R, Ritchie G.
Intermediate care in nursing-led in-patient units: effects
on health care outcomes and resources. Cochrane Database
Syst Rev 2004;CD002214.
Nurses are autonomous professionals
delivering expert care
Editor—It is true that non-medical health-
care professionals, mainly nurses, have
recently taken on a variety of
roles that are traditionally
viewed as the province of
doctors. Clinical evaluations
have generally been positive,
indicating that the skills of
the healthcare team are
being more effectively used
and that similar patient out-
comes can be achieved by
different approaches.1 2
Unfortunately the thinking
of some professionals has
been slower to change, as
exemplified by Cullum and
Spilsbury’s editorial on nurse
led care.3
We object to the statement that doctors
are “delegating” their work to nurses, and
the subsequent implication that only simple
activities will be appropriate for nurse led
care. This statement reinforces the com-
monly held medical view that nurses are
appropriate to fill in where junior doctors
are in short supply and the required tasks
menial, such as pre-assessment clinics and
routine procedures, but not to act as
autonomous professionals initiating and
delivering high quality care. Such outmoded
thinking returns nursing to the status of
“handmaiden.” rather than accepting that
nurses have a specific set of skills and their
own professional accountability.
Experienced nurses have been under-
taking a variety of “medical” tasks for many
years, albeit often in a covert fashion. We
welcome the acknowledgment of the diverse
skills that nursing staff can bring to health
care, and the formal introduction of posts
such as the nurse consultant, which is able to
develop the nursing role while ensuring that
the essence of nursing as profession is not
lost.
Interdisciplinary teams, not doctors,
deliver modern health care. Doctors bring
their particular skills to the team, but no
longer sit at the apex of a hierarchy, delegat-
ing to other professions. Although it may
feel uncomfortable to relinquish the tradi-
tional notion of medical control, doctors
must embrace and support the development
of better health care, regardless of the
professional training of those who deliver it.
Jonathan R Benger consultant in emergency medicine
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Emergency Department, United Bristol Healthcare
Trust, Bristol BS2 8HW
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What’s the evidence that NICE
guidance has been
implemented?
Analysis is subject to confounding
Editor—Sheldon et al show a gradual reduc-
tion in the number of wisdom teeth
extractions, which they propose indicates a
diffusion of guidance from the National Insti-
tute for Clinical Excellence (NICE) into clini-
cal dental practice.1 The first figure in our
response on bmj.com shows the annual
number of courses of treatment that included
at least one extraction of the third molar in
the General Dental Service in Scotland.2 This
figure corresponds to the presentation of
data in figure 1 of Sheldon et al’s paper.1
The raw number of claims per year
masks some underlying trends in the data
that are revealed by weighting the data by
the total number of claims made in the Gen-
eral Dental Service over this period and by
disaggregating the data into those wisdom
tooth extractions that require a surgical pro-
cedure and those that do not.
The figure shows the number of surgical
and non-surgical third molar treatments per
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1000 claims in the Scottish General Dental
Service, as well as the number of general
anaesthetic treatments per 1000 claims in
the Scottish General Dental Service (from
the Management Information and Dental
Accounting System (MIDAS) database,
which is used to process, authorise, and store
all claims for the General Dental Service in
NHS Scotland).
The rate of surgical and non-surgical
extractions varies around a constant rate
until the end of 1998, when the rate of non-
surgical extractions dropped sharply, which
is inconsistent with a pattern of guideline
implementation by diffusion.
New guidance for the administration of
general anaesthesia by dentists in the United
Kingdom was issued by the General Dental
Council and took effect on 10 November
1998.3 The reduction in the rates of
non-surgical extractions coincides with the
change in advice from the dental council to
dentists.
Although the evidence in the figure does
not establish a causal relation between
general anaesthetic treatments and wisdom
teeth extractions, it does provide some pre-
liminary evidence that the regulatory frame-
work within which general dental services are
provided can affect clinicians’ behaviour.
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Maybe NICE needs to do more to ensure
implementation of guidelines
Editor—Sheldon et al investigated whether
guidance from the National Institute for
Clinical Excellence (NICE) has been imple-
mented.1 We found a lack of implementation
of newer guidance.
We examined how NICE guidance, pub-
lished in August 2003, altered prescription
rates of glitazones for type 2 diabetes melli-
tus. NICE recommended that glitazones be
used as a second line treatment in combina-
tion with either metformin or a sulphonyl-
urea in patients with type 2 diabetes who
cannot tolerate metformin and sulphonyl-
urea in combination and for whom these
drugs are contraindicated.2 We postulated
that prescription of glitazones would
increase on the basis of the advice, since the
guidance resulted in a concise framework
for the management of type 2 diabetes.2
The figure shows the numbers of
glitazone prescriptions nationally.We applied
an ARIMA (auto regressive integrated mov-
ing average) model to the data, which led to
no notable changes in prescribing rates as a
result of NICE guidance. P values were 0.40,
0.97, and 0.40 for total prescriptions, pioglita-
zone, and rosiglitazone, respectively.
This absence of difference may be
because the impact is slow and falls outside
the data capture period; the intervention
may have reduced a bigger change; the
“before and after” method is too crude to
detect changes of this type; or our research
was underpowered to detect such changes.
However, our results are another indica-
tion that NICE guidance does not affect
clinical practice. NICE’s premise is com-
mendable, standardising treatments across
the health service and promoting evidence
based health care, but implementing guid-
ance into clinical practice is another
challenge. How the recently assigned “board
level implementation executive” will take on
this mammoth task will be interesting.3
Rishi Mannan intercalated BSc student in primary
health care
Melvyn Jones lecturer in general practice
Department of Primary Care and Population
Sciences, Royal Free and University College
Medical School, London
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Authors’ reply
Editor—Tilley et al are incorrect in
asserting that we said that our findings indi-
cated a diffusion of guidance from the
National Institute for Clinical Excellence
(NICE) into clinical dental practice. To the
contrary, we said that the guidance for
wisdom teeth was published during a long
downward trend in the extraction rate and
did not have a discernible additional effect.
The more disaggregated analysis of
Scottish data they provide is interesting in
showing that one kind of extraction went
down faster in response to guidance linked
to general anaesthetics. However, the
overall trend in the removal of wisdom
teeth when using all four sources of data
including hospital episode statistics is as we
reported. Interestingly, our respondents in
oral surgery departments spoke of a
marked decrease in removals by general
dental practitioners in England that pre-
dated the introduction of the advice on
general anaesthesia.
Mannan and Jones’s data remind us that
we cannot assume that recommendations
will be implemented. This might be aided by
tackling some of the issues that Hine
prompts us to consider as NICE’s fourth
hurdle for the funding of health technolo-
gies becomes more embedded.1
Firstly, mechanisms are needed to
identify technologies for disinvestment,
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which can offset the some of the costs
of new technologies recommended by
NICE, as well as incentives for promoting
disinvestment.
Secondly, recommendations for funding
of new technologies may crowd out the use
of other, possibly more cost effective,
technologies and local priorities that have
not been appraised by NICE.
Thirdly, the overall efficiency and afford-
ability of NICE guidance should be consid-
ered and the need, perhaps, to apply stricter
thresholds whereby technologies would
have to prove greater cost effectiveness
more convincingly before being recom-
mended for mandatory coverage by the
NHS.
These may be better dealt with by NICE
adopting a virtual NHS budget, in which it
has to consider the opportunity costs of its
decisions, and by recommending basic cost
effective packages of care.
Trevor A Sheldon professor
Department of Health Sciences, University of York,
York YO10 5DD
tas5@york.ac.uk
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More recent data on NICE
implementation show different picture
Editor—The National Institute for Clinical
Excellence (NICE) has not recently woken up
to the issue of implementing its guidance, as
Freemantle alleges in his commentary on the
paper by Sheldon et al.1 The institute from its
inception was acutely aware of the impor-
tance of its guidance being incorporated into
routine clinical practice.2
In retrospect it was probably amistake for
NICE not to have been given explicit respon-
sibility for monitoring the implementation of
its guidance at the outset.3 Nevertheless, the
institute’s own concerns, from the beginning,
led NICE to ask the NHS research and devel-
opment programme to commission research
in this area. In June 2004 the institute
launched an implementation support strat-
egy,4 headed by an executive director. In addi-
tion, the Healthcare Commission will put in
place an inspection regime specifically for
NICE guidance.
The study by Sheldon et al covers the
earliest period of the institute’s existence
and pre-dates the direction now requiring
trusts to fund NICE’s appraisal guidance.1 5
More recent studies—of which Freemantle
seems to be unaware—give a somewhat
different picture.
The most extensive has been that under-
taken by Abacus International (www.nice.org.
uk/pdf/Abacus_report.pdf), which covered
28 appraisals, for at least a year and included
ones published after the direction came into
force. The results show that 12 appraisals
were implemented fully, 12 were incom-
pletely implemented, and four over-
implemented. More reviews are available
on the NICE website (www.nice.org.uk/
implementation).
NICE accepts that more needs to be
done to secure full implementation of its
guidance—hence its implementation sup-
port programme. But the facts show that
Freemantle’s incomplete commentary is
very wide of the mark.
Michael Rawlins chairman
lucy.betterton@nice.nhs.uk
Andrew Dillon chief executive
National Institute for Clinical Excellence, London
WC1V 6NA
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Author’s reply
Editor—Despite a spirited defence of the
effectiveness of the National Institute for
Clinical Excellence (NICE), the facts as
described by Rawlins and Dillon do not add
up. Using appropriate quasi experimental
methods, Sheldon et al failed to identify good
evidence that NICE has had an important
impact on clinical practice, at least for the
appraisals that they included in their review.1
This point seems to be accepted by Raw-
lins and Dillon, who direct us towards a
review by Abacus International,2 which they
claim is more complete and up to date. This
review is a simple audit of NHS activity and
lacks the methodological rigour that charac-
terises the paper by Sheldon et al and fails
completely to use appropriate methods to
examine the important issue of causation.
Thus simply choosing areas where NHS
practice was already changing to mirror
NICE guidance would be sufficient for NICE
to appear a success in the Abacus work.
In addition to concerns on the meth-
odological weaknesses of the Abacus
review,2 some may question whether Abacus
International provides objective and unbi-
ased evidence or makes the best case
possible for NICE. Abacus International is a
for profit agency whose usual work entails
providing services for industry. For example,
the Abacus brochure describes how Abacus
can create arguments that:
x Demonstrate that a product is more cost
effective than its competitors
x Facilitate policy decision making despite
shortfalls in long term outcomes data.3
Whatever the truth, two months ago the
then secretary of state for health announced
changes in the organisation of so called
arm’s length bodies, which amount to cuts of
£3.5m ($6.4m; €4.9m) to NICE, to “free up
funding for frontline care.”4 This, coming
from the political masters, is hardly an
unequivocal vote of confidence in the ability
of NICE to influence clinical practice in line
with evidence based guidance on effective
and cost effective care.
Nick Freemantle professor of clinical epidemiology
and biostatistics
University of Birmingham, Birmingham B15 2TT
N.Freemantle@bham.ac.uk
Competing interests: NF has received funding
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Influence of guidelines in
determining medical negligence
Editor—In his article on the influence of
evidence based guidelines in determining
medical negligence Hurwitz argues to reject
guidelines in favour of a “responsible body
of medical opinion,” the fundamental
principle laid down in the Bolam test on the
standard of care, as he cites.1
Eighty eight per cent of specialty guide-
lines did not give any information on
searches,2 yet they are accepted by most
practitioners as the yardstick of clinical prac-
tice. A change in clinical practice on the
basis of evidence based medicine is a recent
phenomenon.3 In 1957, when Bolam was
pronounced, evidence based medicine, spe-
cialty guidelines, and institutions such as the
National Institute for Clinical Excellence
were not known. Therefore the principle
laid down in the Bolam test, that of an ordi-
nary skilled man exercising and professing
to have a special skill, was important to the
court’s decision then.
The General Medical Council recom-
mends following the guidelines. The
Supreme Court of Western Australia
rejected the responsible body of medical
opinion principle in the Bolam test on the
basis of a minority opinion.4 In 1993 a court
rejected that principle by replacing it with a
test of reasonableness as in Bolitho (also
cited by Hurwitz). Farquharson said that,
although the judge may be guided by the
Details of the eight other authors are on
bmj.com
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expert evidence, he or she is not on this
issue to be directed by it. A responsible
medical opinion should be rejected if it is
unreasonable and does not stand up to criti-
cal analysis. Hurwitz then argues that guide-
lines are hearsay, and such evidence is not
accepted in criminal courts or criminal
jurisdiction, but the Bolam test and the cur-
rent discussion are a civil matter. Hearsay
evidence is always accepted in civil court
proceedings.
Guidelines such as those issued by NICE
allow Bolam principles in their grade A to
grade D recommendations.5 Guidelines are
therefore better than a responsible body of
medical opinion.
Kailash C Mohanty consultant physician
Diana, Princess of Wales Hospital, Grimsby DN33
2BA
kailashmohanty@hotmail.com
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Sit up and take notice about
avian flu
Editor—Gottlieb’s report that research
confirms human to human transmission of
avian flu highlights what is now a true threat
to the world’s population.1
The tsunami in Asia illustrated one
acute natural trauma with thousands of
deaths. That catastrophe pales into insignifi-
cance when compared with an influenza
pandemic. Hundreds of millions will die if
the world does not act to prevent this devel-
oping pandemic. Development of vaccines
against H5N1 needs government pump
priming, as will the stockpiling of neurami-
nidase inhibitors, which should be effective
against avian flu.
General practitioners and other pre-
scribing practitioners must learn the practi-
calities of treating epidemic or pandemic
influenza and be prepared to prescribe
appropriately in all cases of true influenza,
to gain experience with the available drugs
as well as encouraging increased pharma-
ceutical company capacity.
It is many years since a pandemic struck,
and people have become complacent in that
time. For governments to bury their heads in
the sand may have some benefits in many
political areas but it will be disastrous in
terms of pandemic planning.
Nigel Higson general practitioner
Goodwood Court Medical Centre, Hove BN3 3DX
surgery@goodwoodcourt.org
Competing interests: None declared.
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Long term sickness absence
Sickness absence, stress, and disaffection
are linked
Editor—A great deal of sickness absence, as
mentioned in the article by Henderson et al,1
arises from the worrying trend to medicalise
life. Much absence due to work related stress
is in fact disaffection rather than disease. It
manifests itself as unhappiness and anxiety
with the working environment and becomes
a withdrawal from work legitimised as a
medical problem through certified absence.
Most healthy people of average fortitude
who are given work that is interesting, satis-
fying, properly resourced, and professionally
managed will turn up to do it. There is
abundant evidence that such work is good
for long term health. The reverse is also true.
The common belief held by bad employers
and some politicians that people are
naturally work shy is an urban myth.
We need better management rather than
better medicine. Good occupational physi-
cians should use their influence to encour-
age good management in their own
organisations, to make sure that stress risks
are systematically and professionally
assessed and be at the heart of rehabilitation
in concert with the general practitioner.
Good general practitioners will work with us
to get their patients back to work.
With an ageing workforce and a difficult
and rigorous pensions climate we are all
going to be at work for much longer than
before. Long term incapacity due to stress
and early retirements, often on tiny pensions,
are not sustainable options for the economy,
pension funds, the NHS, or the future.
We have warehouses full of research and
policies all saying the same things. What we
now need is action on behalf of employers
who believe that decency in the workplace
makes good health and therefore business
sense matched with action by doctors who
believe that work should be part of their
patients’ solution, not their problem.
Dale Archer occupational health physician
Occupational Health Unit, Shropshire County
Council, Shirehall, Shrewsbury SY2 6ND
dalearcher@blueyonder.co.uk
Competing interests: None declared.
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Motivation rather than ability to work
may be key
Editor—Henderson et al write that sickness
absence is a major public health and
economic problem.1 Undoubtedly, it is a
major economic problem, but apparently it
does not serve as an appropriate tool to
measure public health.
Norway has some of the highest
incidences of sickness absence in the world,
but only 10% of the working population is
responsible for over 80% of the absence.2
Disorders of various origins that often lead
to disability and unemployment have largely
been neglected in medical research. The
core complaints are often subjective and
cannot be demonstrated by objective testing.
Apparently reasons for sickness absence
have been considered political problems
and have not gained sufficient attention
from the medical and scientific communi-
ties. Methodologically rigorous, longitudi-
nal, and interventional studies are needed to
determine characteristics that are associated
with the motivation to work rather than the
ability. Interventions that seem effective in
restoring this interest are needed in most
industrialised countries. Such studies need
to be directed towards the 10% that contrib-
ute to 80% of the absence, and not towards
the entire working population.
Ulf R Dahle senior scientist
Norwegian Institute of Public Health, PO Box 4404
Nydalen, 0403 Oslo, Norway
ulf.dahle@fhi.no
Fernanda C Petersen postdoctoral fellow
Institute of Oral Biology, Dental Faculty, PO Box
1052 Blindern, University of Oslo, N-0316 Oslo
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General practitioners have crucial role
but need political support
Editor—I believe that general practitioners,
with their records and knowledge of these
common conditions, are in the best position
to make decisions on absence from work.1
However, the system needs to change to
reflect the greyness ofmost of these decisions.
In some conditions there are no issues about
absence—for example, severe angina. How-
ever, in many conditions prompting a review
of the fitness to work, the clarity of the need to
refrain can vary from reasonable to dubious/
not indicated. These descriptions would
change depending on how long the patient
has been off work already.
Is there some way the general practi-
tioner could indicate that status which would
allow the employer or the benefits agency to
add their opinion and even make the
decision? The general practitioner can give
an opinion that it is not clear whether the
patient should work and whether working is
unlikely to seriously impair the patient’s
health and then the employer or the benefits
agency could use their knowledge of the job
or jobs available to make a decision.
We need a more sophisticated system
that retains decisiveness and speed.We need
a system that does not put someone who is
blind and has had both legs amputated in
the same group as a young man with mild
chronic depression. That system also needs
to use the general practitioner’s skills and
knowledge in a way that does not threaten
the general practitioner’s therapeutic rela-
tionship with the patient.
Graeme M Mackenzie general practitioner
Whitehaven, Cumbria CA28 7RG
graeme.mackenzie@gp-a82041.nhs.uk
Competing interests: None declared.
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